258 related articles for article (PubMed ID: 36602799)
61. Tumor mutational burden and efficacy of chemotherapy in lung cancer.
Song J; Yan Y; Chen C; Li J; Ding N; Xu N; Bao H; Zhang X; Hong Q; Zhou J; Shao YW; Song Y; Tong L; Hu J
Clin Transl Oncol; 2023 Jan; 25(1):173-184. PubMed ID: 35995891
[TBL] [Abstract][Full Text] [Related]
62. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
63. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
[TBL] [Abstract][Full Text] [Related]
64. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.
Bryant AK; Sankar K; Strohbehn GW; Zhao L; Daniel V; Elliott D; Ramnath N; Green MD
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):752-758. PubMed ID: 35450753
[TBL] [Abstract][Full Text] [Related]
65. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
[TBL] [Abstract][Full Text] [Related]
66. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
67. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
[TBL] [Abstract][Full Text] [Related]
68. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
69. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Lobefaro R; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar-Nana F; Ponce S; Dal Maso A; Spotti M; Mielgo-Rubio X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier J; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Planchard D; Mezquita L
Eur J Cancer; 2022 May; 167():142-148. PubMed ID: 35307254
[TBL] [Abstract][Full Text] [Related]
70. Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA; Ramalingam SS; Bradley JD; Higgins KA
Cancer; 2023 Dec; 129(23):3713-3723. PubMed ID: 37354070
[TBL] [Abstract][Full Text] [Related]
71. Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer.
Deek MP; Yegya-Raman N; Daroui P; Balasubramanian S; Malhotra J; Moore D; Patel M; Wang SJ; Aisner J; Jabbour SK
Ann Palliat Med; 2021 Jul; 10(7):7205-7213. PubMed ID: 34263627
[TBL] [Abstract][Full Text] [Related]
72. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
73. Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
Higgs BW; Morehouse CA; Streicher K; Brohawn PZ; Pilataxi F; Gupta A; Ranade K
Clin Cancer Res; 2018 Aug; 24(16):3857-3866. PubMed ID: 29716923
[No Abstract] [Full Text] [Related]
74. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
[TBL] [Abstract][Full Text] [Related]
75. KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials.
Zhu H; Xie D; Yu Y; Yao L; Xu B; Huang L; Wu S; Li F; Zheng Y; Liu X; Xie W; Huang M; Li H; Zheng S; Zhang D; Qiao G; Chan LWC; Zhou H
Front Oncol; 2021; 11():659200. PubMed ID: 34381706
[TBL] [Abstract][Full Text] [Related]
76. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
Calabrò L; Rossi G; Morra A; Rosati C; Cutaia O; Daffinà MG; Altomonte M; Di Giacomo AM; Casula M; Fazio C; Palmieri G; Giannarelli D; Covre A; Maio M
Lancet Respir Med; 2021 Sep; 9(9):969-976. PubMed ID: 33844995
[TBL] [Abstract][Full Text] [Related]
77. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.
Liu Y; Yao L; Kalhor N; Carter BW; Altan M; Blumenschein G; Byers LA; Fossella F; Gibbons DL; Kurie JM; Lu C; Skoulidis F; Chang JY; Liao Z; Gomez DR; O'Reilly M; Heymach JV; Tsao AS; Lin SH
Lung Cancer; 2022 Dec; 174():112-117. PubMed ID: 36371941
[TBL] [Abstract][Full Text] [Related]
78. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
79.
Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
[TBL] [Abstract][Full Text] [Related]
80.
Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]